United Capital Financial Advisers LLC Trims Stock Holdings in TG Therapeutics Inc (NASDAQ:TGTX)

United Capital Financial Advisers LLC decreased its stake in TG Therapeutics Inc (NASDAQ:TGTX) by 5.1% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 56,000 shares of the biopharmaceutical company’s stock after selling 3,000 shares during the period. United Capital Financial Advisers LLC’s holdings in TG Therapeutics were worth $484,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Aperio Group LLC acquired a new stake in TG Therapeutics during the 2nd quarter worth about $32,000. Bank of Montreal Can lifted its stake in shares of TG Therapeutics by 1,119.0% in the 2nd quarter. Bank of Montreal Can now owns 8,143 shares of the biopharmaceutical company’s stock worth $70,000 after acquiring an additional 7,475 shares during the period. BNP Paribas Arbitrage SA lifted its stake in shares of TG Therapeutics by 239.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 13,117 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 9,255 shares during the period. Cutter & CO Brokerage Inc. acquired a new stake in shares of TG Therapeutics in the 2nd quarter worth approximately $176,000. Finally, Parametric Portfolio Associates LLC lifted its stake in shares of TG Therapeutics by 45.4% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 21,152 shares of the biopharmaceutical company’s stock worth $183,000 after acquiring an additional 6,609 shares during the period. Institutional investors and hedge funds own 52.96% of the company’s stock.

Shares of NASDAQ TGTX traded down $0.26 during midday trading on Tuesday, reaching $5.76. The company’s stock had a trading volume of 422,419 shares, compared to its average volume of 1,096,328. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 2.77. The company has a 50 day moving average price of $6.51 and a 200 day moving average price of $7.29. TG Therapeutics Inc has a one year low of $3.32 and a one year high of $9.38.



TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.01. TG Therapeutics had a negative net margin of 99,488.13% and a negative return on equity of 496.99%. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. Equities research analysts expect that TG Therapeutics Inc will post -1.52 earnings per share for the current fiscal year.

In other TG Therapeutics news, CEO Michael S. Weiss bought 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 26th. The shares were acquired at an average cost of $7.04 per share, for a total transaction of $352,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Sean A. Power sold 17,654 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $8.47, for a total transaction of $149,529.38. The disclosure for this sale can be found here. 14.20% of the stock is owned by insiders.

A number of analysts have recently weighed in on TGTX shares. BidaskClub lowered shares of TG Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. ValuEngine raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 15th. Finally, B. Riley reaffirmed a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, June 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. TG Therapeutics has an average rating of “Buy” and a consensus target price of $14.07.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Featured Article: How does a security become overbought?

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics Inc (NASDAQ:TGTX).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.